HOUSTON, Aug. 5, 2020 /PRNewswire/ -- Soliton, Inc.,
(Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary aesthetic platform technology,
today announced the appointment of Dr. Sachin Shridharani to its Scientific Advisory
Board, effective immediately.
"Dr. Shridharani is an extremely talented and accomplished
medical professional, and we are elated to have him join our
Scientific Advisory Board. As Soliton plans to include high quality
plastic surgery offices in the US commercialization of our RAP
device, his extensive experience in aesthetic plastic surgery and
leadership in innovative cosmetic practices will prove invaluable,"
stated Christopher Capelli, MD,
founder, President and CEO of Soliton.
"There is a significant unmet demand for a noninvasive, painless
treatment for cellulite that is effective and has no bruising and
minimal to no patient downtime," commented Dr. Shridharani. "I feel
Soliton's technology has tremendous opportunity once it is approved
for this indication. The mechanism of action appears to be unique,
and I am excited to work with the Company on other indications this
technology may be able to address."
Soliton's RAP technology has not yet been cleared by the FDA for
cellulite reduction and is not available for sale in the United States for this indication.
------------------------
Join our more than 200K
subscribers here to follow the
Company: https://soly-investors.com
------------------------
Dr. Sachin M. Shridharani is a
renowned, Manhattan-based plastic
surgeon, board certified by The American Board of Plastic Surgery
and founder of LUXURGERY – the confluence of luxury and aesthetic
surgery. Dr. Shridharani has co-authored over 200 peer-reviewed
articles, textbook chapters, and abstracts on the topics of
cosmetic and reconstructive surgery in some of the most
well-respected medical journals domestically and internationally,
including the Journal of the American Medical Association
(JAMA) and Plastic and Reconstructive Surgery. Recognized as
an international authority on aesthetic plastic surgery treatments,
technique and research, Dr. Shridharani serves as an international
Global Thought Leader/Key Opinion Leader.
Dr. Shridharani completed his training in Plastic and
Reconstructive Surgery at the prestigious Johns Hopkins Hospital,
where he served as chief resident alongside leaders in the field of
Plastic, Reconstructive, Aesthetic, Craniomaxillofacial, and Hand
Surgery. Following his surgical residency, Dr. Shridharani went on
to complete an Aesthetic Plastic Surgery fellowship at the esteemed
Manhattan Eye, Ear and Throat Hospital where he was mentored by
pioneers in the field of Aesthetic Surgery and Medicine.
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from MD Anderson. The
Company's first FDA cleared commercial product will use rapid
pulses of acoustic shockwaves as an accessory to lasers for the
removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in
bringing the Rapid Acoustic Pulse ("RAP") device to the market. The
Company believes this "Soliton" method has the potential to lower
tattoo removal costs for patients, while increasing profitability
to practitioners, compared to current laser removal methods.
Soliton has completed a clinical study using the RAP device to
improve the appearance of cellulite and is investigating potential
additional capabilities of the RAP technology. The device is
currently cleared in the United
States only for use in tattoo removal and is not yet cleared
for use to address cellulite.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
This press release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995, which statements involve
risks and uncertainties. These statements relate to future events,
future expectations, plans and prospects. Although Soliton believes
that the expectations reflected in such forward-looking statements
are reasonable as of the date made, actual results or outcomes may
prove to be materially different from the expectations expressed or
implied by such forward-looking statements. Soliton has attempted
to identify forward-looking statements by terminology including
''believes,'' ''estimates,'' ''anticipates,'' ''expects,''
''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,''
''could,'' ''might,'' ''will,'' "would," ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
in our filings with the Securities and Exchange Commission ("SEC"),
including under the heading " Risk Factors" in the Form 10-K for
year ended December 31, 2019 filed
with the SEC and as updated in our Form 10-Q filings and in our
other filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. Soliton
undertakes no obligation to update any forward-looking statements
contained in this release to reflect events or circumstances
occurring after its date or to reflect the occurrence of
unanticipated events.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/soliton-appoints-dr-sachin-shridharani-to-scientific-advisory-board-301106326.html
SOURCE Soliton, Inc.